Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148
Recommend 3 Positive 5 Negative 3 |
||||
|
||||
|
RemeGen (09995.HK) announced that it has received an upfront payment of USD650 million from AbbVie (through its holding company) under an exclusive licensing agreement for RC148, a novel PD-1/VEGF bispecific antibody independently developed by the company. The collaboration between the two parties is currently progressing smoothly. (ha/da) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
